^
Association details:
| Biomarker: | FGFR1 overexpression |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer
Excerpt:
To explore whether overexpression of FGFR1 is causal to resistance to alpelisib, we first examined the effect of alpelisib in the ER+ CAMA-1 breast cancer cells...Altogether, these data suggest a causal association between FGFR1 overexpression and activation of ERK with relative resistance to alpelisib.
Secondary therapy:
letrozole
DOI:
10.1158/1078-0432.CCR-16-0134
